- Modulation of human cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome b52014 | Faculty of Science, Second Faculty of Medicine
- Modulation of human cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome b(5)2014 | Faculty of Science, Second Faculty of Medicine
- Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency2011 | First Faculty of Medicine
- Diminished FAD-binding specificity in human cytochrome P450 oxidoreductase associated with Antley-Bixler syndromePublication without faculty affiliation
- Diminished FAD-binding in human cytochrome P450 oxidoreductase associated with Antley-Bixler syndrome mutant Y459H and V492EPublication without faculty affiliation
- Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers2018 | Faculty of Science
- Crystal structure of the FAD/NADPH-binding domain of rat neuronal nitric-oxide synthase - comparisons with NADPH-cytochrome P450 oxidoreductase2001 | First Faculty of Medicine
- The Anticancer Drug Ellipticine Induces Cytochromes P450 1A1, 1A2 and 3A, Cytochrome b(5) and NADPH:Cytochrome P450 Oxidoreductase in Rat Liver, Kidney and Lung2013 | Faculty of Science
- Cytochronne b(5) and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions2014 | Faculty of Science, Central Library of Charles University
- Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype2016 | First Faculty of Medicine
- Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort2015 | First Faculty of Medicine
- Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and P-32-postlabelling2012 | Faculty of Science
- Studies with the hepatic NADPH:cytochrome P450 reductase null mouse reveal the role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine2007 | Faculty of Science
- Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by P-32-postlabeling2018 | Faculty of Science
- The Role of Cytochrome P450 Enzymes in Carcinogen Metabolism: Lessons Learned From Studies With Benzo[a]pyrene and Aristolochic Acid2018 | Faculty of Science
- Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization2011 | First Faculty of Medicine
- Effect of Hepatic Cytochrome P450 (P450) Oxidoreductase Deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine- DNA Adduct Formation in P450 Reductase Conditional Null Mice2011 | Faculty of Science
- Quercetin Induces Hepatic Lipid Omega-Oxidation and Lowers Serum Lipid Levels in Mice2013 | First Faculty of Medicine
- The Hepatic Reductase Null (HRN (TM)) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants2015 | Faculty of Science
- Cytochrome b(5) impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b(5)/P450 reductase null (HBRN) mice2018 | Faculty of Science
- Application of hepatic cytochrome b(5)/P450 reductase null (HBRN) mice to study the role of cytochrome b(5) in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine2019 | Faculty of Science